Natural Killer Cells and Mogamulizumab for T-cell Lymphomas
This study is testing a combination of two treatments, Natural Killer Cell Therapy and mogamulizumab, for people with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that has returned or isn't responding to other treatments. Natural Killer Cell Therapy uses special immune cells to fight cancer, and mogamulizumab is an antibody that can stop cancer cells from growing. Researchers want to find the safest and most effective dose of these treatments together. They will also look at how well the treatment shrinks tumors and improves quality of life. This study is currently unclear on its recruitment status and plans to enroll 12 participants.
- Study design
- This is a dose-escalation study, meaning participants will receive increasing doses of the treatments to find the safest amount. It is an interventional study, but the phase is not specified.
- What's involved
- You would receive cyclophosphamide and fludarabine intravenously (IV), followed by Natural Killer Cell Therapy infusions every two weeks for six total infusions. You would also receive mogamulizumab IV on specific days, continuing as long as the treatment is working and well-tolerated.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure adverse events (side effects) for up to 84 days after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT04848064
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Recruiting
PHASE1Ages 18+InterventionalTreatmentJohn ReneauInvestigator-initiated
~12 participants
Updated 2026-02-10 on ClinicalTrials.gov
What's tested:CyclophosphamideFludarabineMogamulizumabNatural Killer Cell TherapyQuality-of-Life AssessmentQuestionnaire Administration
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of adverse events
Measured over Up to day 84
Conditions
NCT04848064
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Ohio State University Comprehensive Cancer Center
Columbus, Ohiostudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- John C Reneau, MD, PhD · PRINCIPAL_INVESTIGATOR · Ohio State University Comprehensive Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Able to understand and voluntarily sign an informed consent form
Age \>= 18 years at the time of signing the informed consent form
Able to adhere to the study visit schedule and other protocol requirements
Biopsy-proven, measurable, stage IB-IVB relapsed or refractory cutaneous T-cell lymphoma after 1 prior line of systemic therapy
Note: extracorporeal photopheresis will be considered a systemic therapy for this study
Patients with large cell transformation of cutaneous T cell lymphoma are eligible
Patients with adult T-cell leukemia/lymphoma (ATLL) of any stage and any subtypes. Patient must have had at least one standard chemotherapy and measurable disease at the time of enrollment
Patients who relapsed after autologous or allogeneic stem cell transplant are eligible
All cancer therapy, including radiation, topical steroid, and chemotherapy must have been discontinued at least 1 week or 3 half-lives whichever is the longest prior to treatment in this study. The only exceptions are participants who are symptomatic from their skin lesions and have been on corticosteroids for prolonged periods of time (\> 60 days) without change. These patients may continue use of either systemic steroids (equivalent to \< 10 mg per day of prednisone) or topical steroids if the frequency and dosage steroids has not changed for 21 days prior to the study. These participants should continue on the same dose of systemic/topical steroid throughout the study period unless they achieve a complete response at which time steroids can be tapered or discontinued. Patients are allowed to continue any medications with known activity in T cell lymphomas at the pre-enrollment doses for conditions other than T cell lymphomas (ie, steroids for sarcoidosis), as long as there is evidence of T cell lymphoma progression while patients were on these agents
Eastern Cooperative Oncology Group (ECOG) performance status of =\< 1 at study entry
Absolute neutrophil count \>= 1000/mm\^3
Platelet count \>= 50,000/mm\^3
Total bilirubin =\< 2 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and Alanine Aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) =\< 3 x ULN
AST (SGOT) and ALT (SGPT) =\< 5 x ULN in patients with documented hepatic involvement by lymphoma
Calculated creatinine clearance \>= 50 ml/min (by the Crockroft-Gault equation)
Disease free of prior malignancies for \>= 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast. Patients with early stage of prostate cancer under clinical surveillance without therapy are eligible. Patients with B-cell lymphomas treated with curative intent, and in remission for at least 2 years, may be in included (after discussion with principal investigator \[PI\])
Negative serum pregnancy test at the time of enrollment for females of childbearing potential. Women who can get pregnant and men with partners who can become pregnant will be asked to practice a highly effective method of birth control while participating in the study that is considered medically acceptable by the study doctor.
Life expectancy \>= 90 days
Any illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety
A cardiovascular disability status of New York Heart Association class \>= 2
History of severe allergic reactions to humanized monoclonal antibodies
History of other malignancy that could affect compliance with the protocol or interpretation of results. Patients with a history of curatively treated basal or squamous cell carcinoma or Stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible. Patients with early stage of prostate cancer under clinical surveillance without therapy are eligible
Known hypersensitivity to any of the study drugs or analogs
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior study therapy
Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Recent major surgery (within 6 weeks prior to the start of study treatment) other than for diagnosis
Receiving immunosuppressive therapy
Prior therapy with mogamulizumab unless stopped previously for reasons other than progression or toxicity.
Pregnant or lactating, or intending to become pregnant during the study
Exclusion
Investigational therapies in the 2 weeks prior to beginning treatment on trial
Patients with active central nervous system (CNS) involvement with lymphoma
Patients with known human immunodeficiency virus (HIV) infection with CD4 \< 350
Patients who had solid organ transplants
Evidence of active hepatitis B infection, based on positive surface antigen or hepatitis B deoxyribonucleic acid (DNA) polymerase chain reaction (PCR), or active hepatitis C infection based on positive PCR. Patients who are hepatitis B core antibody positive must take prophylaxis with lamivudine or equivalent and be willing to undergo monthly hepatitis B DNA PCR testing
Present or history of progressive multifocal leukoencephalopathy (PML)
Active grade II-IV acute or extensive chronic graft versus (vs.) host disease (GVHD)
What this trial measures
- Incidence of adverse eventsUp to day 84
Toxicities will be captured by Common Terminology Criteria for Adverse Events version 5. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. The incidence of severe adverse events or toxicities will be described. Will assess the proportion of patients who experience grade 3 or higher non-hematologic toxicity.